Basic Information
Onureg
Regulatory Information
EMEA/H/C/004761
June 17, 2021
April 22, 2021
2
February 18, 2025
Company Information
Ireland
Plaza 254 Blanchardstown Corporate Park 2 Dublin 15 D15 T867
Bristol-Myers Squibb Pharma EEIG
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT).
Overview Summary
Onureg is a cancer medicine used to treat acute myeloid leukaemia (AML), a cancer of white blood cells. It is used for maintenance treatment after the initial cancer treatment has brought the disease under control, in patients who cannot be given haematopoietic stem cell transplantation (a procedure to replace the cells that produce blood cells) to prevent the cancer coming back. Onureg contains the active substance azacitidine.